ClinicalTrials.gg
CompletedNCT00270634PROMISEUpdated Feb 12, 2013Results posted

Study of ISA247 (Voclosporin) in De Novo Renal Transplantation

A Phase 2 interventional study of Voclosporin and tacrolimus in Kidney Diseases, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 45 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-02-12.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing tacrolimus in Kidney Diseases — none open to participants now, 1 under way, 1 of them phase 3. Tacrolimus · Kidney Diseases.

Enrollment
2nd of 13
334 · median 94
Started
2006
with 2 others
Phase 2
Only one
of the 13
Registered
3rd of 13
by date
Lead sponsor
1 of 13
Aurinia Pharmaceuticals Inc.

Among the 13 studies testing tacrolimus in Kidney Diseases, this one is the 2nd largest by enrollment, is one of 3 that started in 2006, is the only one in phase 2, and was the 3rd registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

None of the 13 studies testing tacrolimus in Kidney Diseases is open now. The open studies under Kidney Diseases, anywhere →

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing tacrolimus in Kidney Diseases as a file.
02

Study summary

This study will see if voclosporin is safe and effective in preventing kidney transplant rejection.

Read the detailed description

Prograf® (tacrolimus) is associated with numerous side effects, including neurotoxicity, nephrotoxicity, polyoma nephropathy, QT prolongation, and New Onset Diabetes Mellitus After Transplant (NODAT). Voclosporin is a novel calcineurin inhibitor intended for use in the prevention of organ graft rejection.

Comparison(s): Voclosporin at 3 dose levels (0.4, 0.6, and 0.8 mg/kg twice a day) compared to tacrolimus

03

Conditions studied

  • Kidney Diseases

Browse trials for

Keywords

  • Randomized Controlled Trials
  • Immunosuppression
  • Adult
  • Kidney Transplantation
  • Treatment Outcome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 18 - 65 years inclusive at the time of screening.
  • Patients must be receiving a first cadaveric or living donor renal transplant.
  • Patients must be able to receive oral medication at time of randomization.
  • Females who are not pregnant or nursing or planning to become pregnant during the course of the study, or 3 months after last dose of study medication.
  • Sexually-active women of (including those who are \< 1 year ) and sexually-active men who are practicing a highly effective method of . A highly effective method of birth control is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly and will include implants, injectables, combined oral contraceptives, double-barrier method, sexual abstinence, or a sterile partner. Sexually-active men and women of child-bearing potential should continue to practice contraception as outlined above during treatment and for ≥ 3 months after the last dose of voclosporin.
  • Able to give written prior to screening procedures.
  • Able to keep study appointments and cooperate with all study requirements, in the opinion of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Receiving a HLA (human leukocyte antigen)identical living related transplant.
  • Cold ischemic time > 24 hours.
  • Peak PRA (panel reactive antibodies) > 30%
  • Cadaveric donors who are over age 60, non-heart beating donors, or any cadaveric donors positive for , virus (HBV) or virus (HCV).
  • Transplantation of multiple grafts (e.g. kidney and pancreas).
  • Systemic infections requiring continued therapy at the time of entry into this study. (Prophylaxis against cytomegalovirus [CMV] and/or pneumocystis carinii pneumonia (PCP) infection will be permitted).
  • Serologic evidence or known latent human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) virus. Known negative serology prior to study entry may be used.
  • A current or history of malignancy within 5 years or a history of lymphoma at any time. Subjects can be enrolled with a history of squamous or basal cell carcinoma that has been surgically excised or removed with curettage and electrodesiccation.
  • Requires prohibited medications or treatment during the study.
  • (ALT), aspartate transaminase (AST), or gamma-glutamyl transferase (GGT) ≥ 3x (ULN) at time of transplantation.
  • White blood cell count ≤ 2.8 x 10\^9/L.
  • Triglycerides ≥ 3x ULN.
  • Pregnant women or nursing mothers.
  • Has used any drug or device within 28 days or 5 half lives (whichever is longer) prior to enrollment.
  • Previous exposure to voclosporin.
  • A history of active alcoholism or drug addiction within 1 year prior to study entry.
  • Weighs \< 45 kg (99 lbs) or > 140 kg (308 lbs).
  • A history of disease, including mental/emotional disorder that would interfere with the subject's participation in the study, or that might cause the administration of voclosporin to pose a significant risk to the subject, in the opinion of the investigator.
  • Allergy to iodine.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
334 participants (actual)

Study arms

  • Active comparator
    Low Dose Voclosporin

    Low dose voclosporin

    Drug: Voclosporin

  • Active comparator
    Mid Dose Voclosporin

    Mid Dose Voclosporin

    Drug: Voclosporin

  • Active comparator
    High Dose Voclosporin

    High Dose Voclosporin

    Drug: Voclosporin

  • Active comparator
    Tacrolimus

    Standard Dose Tacrolimus

    Drug: tacrolimus

Interventions

  • voclosporin 0.4, 0.6, 0.8 mg/kg po BID

    Also known as: ISA247

  • tacrolimus 0.05 mg/kg po BID

06

What researchers measure

Primary outcomes

  1. Biopsy Proven Acute Rejection (BPAR)

    The primary objective of the PROMISE trial was to demonstrate noninferiority of biopsy proven acute rejection (BPAR) rate in de novo renal transplant patients at 6 months in at least one VCS treatment group.

    Time frame: Six months

Secondary outcomes

  1. To Demonstrate a 5% Improvement in Renal Function as Measured by Iothalamate Glomerular Filtration Rate (GFR)

    ANOVAs to test for differences in GFR at Month 6.

    Time frame: Six months

  2. The Pharmacokinetic-pharmacodynamic Relationship Between Voclosporin and Calcineurin Inhibition (CNi), or Tacrolimus and Calcineurin Inhibition

    A sparse sampling protocol of whole blood samples obtained on Day 180 at time points immediately prior to drug administration and at 1, 2, and 4 hours post-dose were utilized. Standard non-compartmental analysis (NCA) was performed on whole blood concentration data for voclosporin and its metabolites, tacrolimus, MPA (mycophenolic acid) and MPAG (mycophenolic acid glucuronide). Tmax and Cmax were obtained directly from the concentration-time profiles without interpolation. AUC(0-4)\[area under the curve\] was calculated using log-linear trapezoidal rule. Cmax, AUC(0-4), C0 and C2 were summarized using descriptive statistics.

    Time frame: Six months

  3. Patient Survival

    Time frame: Six months

  4. Graft Survival

    Time frame: Six months

  5. Hypertension, Hyperlipidemia, or Hyperglycemia

    Time frame: Six months

  6. A Composite of Biopsy-proven Chronic Rejection Graft Loss, Death, or Lost to Follow up.

    Time frame: Six months

07

Results

Posted Feb 12, 2013
Limitations and caveats
By limiting access to patients at relatively low risk for rejection and no delayed graft function, the results observed may not be applicable to all renal transplant recipients.

Participant flow

A total of 334 de novo renal transplant patients were recruited in 36 US and 4 Canadian transplant centres between January 2006 and December 2007.

Participant flow — Overall Study
MilestoneHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
Started87778486
Completed70646281
Not completed1713225

Outcome measures

PrimaryBiopsy Proven Acute Rejection (BPAR)

The primary objective of the PROMISE trial was to demonstrate noninferiority of biopsy proven acute rejection (BPAR) rate in de novo renal transplant patients at 6 months in at least one VCS treatment group.

Time frame:
Six months
Reported as:
Number · percentage of participants
Biopsy Proven Acute Rejection (BPAR)
percentage of participantsHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
Biopsy Proven Acute Rejection (BPAR)2.3 (— to 1.3)9.1 (— to 10.8)10.7 (— to 11.4)5.8 (0 to 0)
Statistical analysis
  • High Dose Voclosporin vs Tacrolimus · t-test, 1 sided · Weighted average difference: -3.2The upper bound of the confidence interval was a measure of non-inferiority of VCS to TAC. VCS was considered non-inferior to TAC if the upper one-sided 95% confidence bound was less than 15%.
  • Mid Dose Voclosporin vs Tacrolimus · t-test, 1 sided · Weighted average difference: 4.6The upper bound of the confidence interval was a measure of non-inferiority of VCS to TAC. VCS was considered non-inferior to TAC if the upper one-sided 95% confidence bound was less than 15%.
  • Low Dose Voclosporin vs Tacrolimus · t-test, 1 sided · Weighted average difference: 4.9The upper bound of the confidence interval was a measure of non-inferiority of VCS to TAC. VCS was considered non-inferior to TAC if the upper one-sided 95% confidence bound was less than 15%.
SecondaryTo Demonstrate a 5% Improvement in Renal Function as Measured by Iothalamate Glomerular Filtration Rate (GFR)

ANOVAs to test for differences in GFR at Month 6.

Time frame:
Six months
Reported as:
Mean · mL/min
To Demonstrate a 5% Improvement in Renal Function as Measured by Iothalamate Glomerular Filtration Rate (GFR)
mL/minHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
To Demonstrate a 5% Improvement in Renal Function as Measured by Iothalamate Glomerular Filtration Rate (GFR)68 ± 1372 ± 1271 ± 1369 ± 29
SecondaryThe Pharmacokinetic-pharmacodynamic Relationship Between Voclosporin and Calcineurin Inhibition (CNi), or Tacrolimus and Calcineurin Inhibition

A sparse sampling protocol of whole blood samples obtained on Day 180 at time points immediately prior to drug administration and at 1, 2, and 4 hours post-dose were utilized. Standard non-compartmental analysis (NCA) was performed on whole blood concentration data for voclosporin and its metabolites, tacrolimus, MPA (mycophenolic acid) and MPAG (mycophenolic acid glucuronide). Tmax and Cmax were obtained directly from the concentration-time profiles without interpolation. AUC(0-4)\[area under the curve\] was calculated using log-linear trapezoidal rule. Cmax, AUC(0-4), C0 and C2 were summarized using descriptive statistics.

Time frame:
Six months
Reported as:
Mean · % Calcineurin (CNi) compared to baseline
The Pharmacokinetic-pharmacodynamic Relationship Between Voclosporin and Calcineurin Inhibition (CNi), or Tacrolimus and Calcineurin Inhibition
% Calcineurin (CNi) compared to baselineHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
The Pharmacokinetic-pharmacodynamic Relationship Between Voclosporin and Calcineurin Inhibition (CNi), or Tacrolimus and Calcineurin Inhibition57.3 ± 14.447.5 ± 16.438.8 ± 16.323.0 ± 13.8
SecondaryPatient Survival
Time frame:
Six months
Reported as:
Number · Percentage of patients
Patient Survival
Percentage of patientsHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
Patient Survival98.910010097.7
SecondaryGraft Survival
Time frame:
Six months
Reported as:
Number · Percentage of patients
Graft Survival
Percentage of patientsHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
Graft Survival98.910010097.7
SecondaryHypertension, Hyperlipidemia, or Hyperglycemia
Time frame:
Six months
Reported as:
Number · Percentage of patients
Hypertension, Hyperlipidemia, or Hyperglycemia
Percentage of patientsHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
Treatment with an Antihypertensive96.6 ± 197.4 ± 196.4 ± 1.295.3 ± 1.2
Triglyceride values > ULN28 ± 1830 ± 1818 ± 2239 ± 16
New Onset of Diabetes Mellitus After Transplant17.75.71.616.4
SecondaryA Composite of Biopsy-proven Chronic Rejection Graft Loss, Death, or Lost to Follow up.
Time frame:
Six months
Reported as:
Number · Percentage of patients
A Composite of Biopsy-proven Chronic Rejection Graft Loss, Death, or Lost to Follow up.
Percentage of patientsHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
A Composite of Biopsy-proven Chronic Rejection Graft Loss, Death, or Lost to Follow up.5.67.43.73.9

Adverse events

Collected over 6 month treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Dose Voclosporin—40/87 (46%)84/87 (96.6%)
Mid Dose Voclosporin—35/77 (45.5%)76/77 (98.7%)
Low Dose Voclosporin—36/84 (42.9%)83/84 (98.8%)
Tacrolimus—37/86 (43%)85/86 (98.8%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
Kidney Transplant RejectionImmune system disorders4/8710/7718/846/86
Blood Creatinine IncreasedInvestigations6/873/773/843/86
HydronephrosisRenal and urinary disorders0/874/770/842/86
PyrexiaGeneral disorders1/873/770/843/86
DehydrationMetabolism and nutrition disorders3/871/770/843/86
Complications of Transplanted KidneyInjury, poisoning and procedural complications3/870/770/840/86
Urinary Tract InfectionInfections and infestations1/872/770/841/86
HypertensionVascular disorders0/870/772/840/86
GastroenteritisInfections and infestations0/870/770/842/86
International Normalised Ratio DecreasedInvestigations0/870/770/842/86
Most frequent other events
Showing 10 of 81
Most frequent other events
EventHigh Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimus
CONSTIPATIONGastrointestinal disorders35/8734/7743/8431/86
DIARRHOEAGastrointestinal disorders31/8729/7716/8443/86
HYPOMAGNESAEMIAMetabolism and nutrition disorders34/8721/7722/8437/86
NAUSEAGastrointestinal disorders36/8728/7736/8435/86
HYPOPHOSPHATAEMIAMetabolism and nutrition disorders28/8732/7732/8434/86
OEDEMA PERIPHERALGeneral disorders28/8731/7724/8423/86
INSOMNIAPsychiatric disorders20/8720/7719/8433/86
PROCEDURAL PAINInjury, poisoning and procedural complications29/8728/7728/8430/86
ANAEMIABlood and lymphatic system disorders27/8724/7730/8427/86
HYPERTENSIONVascular disorders23/8723/7729/8426/86

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)High Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimusTotal
<=18 years00000
Between 18 and 65 years82767982319
>=65 years515415
Sex: Female, Male
Sex: Female, Male(Participants)High Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimusTotal
Female24253331113
Male63525155221
Region of Enrollment
Region of Enrollment(participants)High Dose VoclosporinMid Dose VoclosporinLow Dose VoclosporinTacrolimusTotal
United States74677475290
Canada1310101144
08

Study locations

45 sites
  • Isotechnika Investigational Site
    Birmingham, Alabama 35924, United States
  • Isotechnika Investigational Site
    Los Angeles, California 90033, United States
  • Isotechnika Investigational Site
    Los Angeles, California 90057, United States
  • Isotechnika Investigational Site
    Los Angeles, California 90095-7306, United States
  • Isotechnika Investigational Site
    Orange, California 92868, United States
  • Isotechnika Investigational Site
    Palo Alto, California 94304-1510, United States
  • Isotechnika Investigational Site
    San Diego, California 92123, United States
  • Isotechnika Investigational Site
    San Francisco, California 94143-0116, United States
  • Isotechnika Investigational Site
    Denver, Colorado 80262, United States
  • Isotechnika Investigational Site
    Gainesville, Florida 32610, United States
  • Isotechnika Investigational Site
    Tampa, Florida 33606, United States
  • Isotechnika Investigational Site
    Chicago, Illinois 60611, United States
  • Isotechnika Investigational Site
    Chicago, Illinois 60637, United States
  • Isotechnika Investigational Site
    Lexington, Kentucky 40536, United States
  • Isotechnika Investigational Site
    New Orleans, Louisiana 70112, United States
  • Isotechnika Investigational Site
    New Orleans, Louisiana 70121, United States
  • Isotechnika Investigational Site
    Baltimore, Maryland 21201, United States
  • Isotechnika Investigational Site
    Boston, Massachusetts 02215, United States
  • Isotechnika Investigational Site
    Ann Arbor, Michigan 48109-9623, United States
  • Isotechnika Investigational Site
    Detroit, Michigan 48202, United States
  • Isotechnika Investigational Site
    Rochester, Minnesota 55905, United States
  • Isotechnika Investigational Site
    Livingston, New Jersey 07039, United States
  • Isotechnika Investigational Site
    Buffalo, New York 14203, United States
  • Isotechnika Investigational Site
    Hawthorne, New York 10532, United States
  • Isotechnika Investigational Site
    New York, New York 10021, United States
  • Isotechnika Investigational Site
    Rochester, New York 14642-8410, United States
  • Isotechnika Investigational Site
    Durham, North Carolina 27705, United States
  • Isotechnika Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • Isotechnika Investigational Site
    Cincinnati, Ohio 45219, United States
  • Isotechnika Investigational Site
    Cincinnati, Ohio 45267-0585, United States
  • Isotechnika Investigational Site
    Portland, Oregon 97210, United States
  • Isotechnika Investigational Site
    Portland, Oregon 97239-2940, United States
  • Isotechnika Investigational Site
    Portland, Oregon 97329-2940, United States
  • Isotechnika Investigational Site
    Philadelphia, Pennsylvania 19102, United States
  • Isotechnika Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Isotechnika Investigational Site
    Charleston, South Carolina 29425, United States
  • Isotechnika Investigational Site
    Memphis, Tennessee 38104, United States
  • Isotechnika Investigational Site
    Dallas, Texas 75246, United States
  • Isotechnika Investigational Site
    Houston, Texas 77030, United States
  • Isotechnika Investigational Site
    Richmond, Virginia 23298, United States
  • Isotechnika Investigational Site
    Edmonton, Alberta T6G 2G3, Canada
  • Isotechnika Investigational Site
    London, Ontario N6A 5A5, Canada
  • Isotechnika Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • Isotechnika Investigational Site
    Montreal, Quebec H3A 1A1, Canada
  • Isotechnika Investigational Site
    Saskatoon, Saskatchewan S7M 0Z9, Canada
09

References and documents

Publications

  • Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner A, Griffey SM, Paniagua RT, Hubble RW, Borie DC, Morris RE. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation. 2004 Sep 15;78(5):681-5. doi: 10.1097/01.tp.0000131950.75697.71. PubMed 15371668 ↗
  • Stalder M, Birsan T, Hubble RW, Paniagua RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003 Dec;22(12):1343-52. doi: 10.1016/s1053-2498(03)00033-0. PubMed 14672749 ↗
  • Abel MD, Aspeslet LJ, Freitag DG, Naicker S, Trepanier DJ, Kneteman NM, Foster RT, Yatscoff RW. ISATX247: a novel calcineurin inhibitor. J Heart Lung Transplant. 2001 Feb;20(2):161. doi: 10.1016/s1053-2498(00)00290-4. No abstract available. PubMed 11250240 ↗
  • Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22. PubMed 21943027 ↗
  • Mayo PR, Ling SY, Huizinga RB, Freitag DG, Aspeslet LJ, Foster RT. Population PKPD of voclosporin in renal allograft patients. J Clin Pharmacol. 2014 May;54(5):537-45. doi: 10.1002/jcph.237. Epub 2013 Nov 30. PubMed 24243422 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2005
First posted
Dec 28, 2005
Start
Jan 2006
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Feb 12, 2013
Last update
Feb 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00270634
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Dec 28, 2005
Start date
Jan 2006
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Feb 12, 2013
Last update
Feb 12, 2013

Study contacts

Daniel Abramowicz, MD, PhD
study director · Erasme hospital
Philip Belitsky, MD
study director · No Affiliation
Arthur Matas, MD
study director · University of Minnesota
Mark Pescovitz, MD
study director · Indiana University
A. Osama Gaber, MD
study director · The Methodist Hospital Research Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Voclosporin · Tacrolimus

Start the discussion